文献速递心脑血管急症重症综合管理与镇静镇痛

高剂量与低剂量氨甲环酸输注对心脏手术患者红细胞输注需求及不良事件的影响:OPTIMAL随机临床试验

Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论心脏体外循环手术中,高剂量氨甲环酸较低剂量轻度降低红细胞输注率(21.8% vs 26.0%),且30天死亡、癫痫、肾功能障碍和血栓事件复合终点非劣效。

OPTIMAL多中心双盲随机试验纳入中国4家医院3079例体外循环心脏手术成人患者,比较高剂量氨甲环酸(30 mg/kg负荷+16 mg/kg/h维持+2 mg/kg预充)与低剂量方案(10 mg/kg负荷+2 mg/kg/h维持+1 mg/kg预充)。主要疗效终点为手术开始后异体红细胞输注率,高剂量组21.8% vs 低剂量组26.0%(RD -4.1%,单侧97.55%CI -∞至-1.1%;RR 0.84,P=0.004)。主要安全复合终点(30天死亡、癫痫、肾功能障碍、血栓事件)高剂量组17.6% vs 低剂量组16.8%(RD 0.8%,单侧97.55%CI -∞至3.9%;非劣效P=0.003)。15个次要终点中14个组间无显著差异,癫痫高剂量组1.0% vs 低剂量组0.4%(RD 0.6%,95%CI -0.0%至1.2%;P=0.05)。

要点

  • 高剂量氨甲环酸组异体红细胞输注率21.8%(333/1525)低于低剂量组26.0%(391/1506),RD -4.1%(单侧97.55%CI -∞至-1.1%),RR 0.84(单侧97.55%CI -∞至0.96;P=0.004)。
  • 主要安全复合终点(30天死亡、癫痫、肾功能障碍、血栓事件)高剂量组17.6%(265例)vs低剂量组16.8%(249例),RD 0.8%(单侧97.55%CI -∞至3.9%),非劣效P=0.003,非劣效界值5%。
  • 癫痫发生率在高剂量组1.0%(15例)与低剂量组0.4%(6例)间无统计学显著差异(RD 0.6%,95%CI -0.0%至1.2%;P=0.05)。
  • 15个预设次要终点中有14个组间无显著差异,包括主要安全终点的各单项组分。

适用人群与场景

  • 成人患者,接受体外循环心脏手术。
  • 2018年12月26日至2021年4月21日在中国4家医院入组3079例,最终随访2021年5月21日;3031例(98.4%)完成试验。
  • 平均年龄52.8岁,女性占38.1%。

处置流程与药物剂量

  • 高剂量方案:30 mg/kg负荷剂量,16 mg/kg/h维持剂量,2 mg/kg预充(n=1525)。
  • 低剂量方案:10 mg/kg负荷剂量,2 mg/kg/h维持剂量,1 mg/kg预充(n=1506)。

研究设计与关键结果

  • 多中心、双盲、随机临床试验,纳入3079例体外循环心脏手术成人患者,高剂量组1525例,低剂量组1506例。
  • 主要疗效终点(手术开始后异体红细胞输注率):高剂量组21.8%(333/1525)vs低剂量组26.0%(391/1506),RD -4.1%(单侧97.55%CI -∞至-1.1%),RR 0.84(单侧97.55%CI -∞至0.96;P=0.004)。
  • 主要安全复合终点(术后30天死亡、癫痫、肾功能障碍[KDIGO 2或3期]、血栓事件[心肌梗死、缺血性卒中、深静脉血栓、肺栓塞]):高剂量组17.6%(265例)vs低剂量组16.8%(249例),RD 0.8%(单侧97.55%CI -∞至3.9%),非劣效P=0.003(非劣效界值5%)。
  • 癫痫:高剂量组1.0%(15例)vs低剂量组0.4%(6例),RD 0.6%(95%CI -0.0%至1.2%;P=0.05)。
  • 15个预设次要终点中14个组间无显著差异,包括主要安全终点的各单项组分。

证据类型、等级与局限

  • 研究类型:多中心、双盲、随机临床试验。
  • 非劣效界值5%;主要疗效终点采用优效性假设,主要安全终点采用非劣效性假设。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于体外循环心脏手术成人患者,高剂量氨甲环酸方案(30 mg/kg负荷+16 mg/kg/h维持+2 mg/kg预充)较低剂量方案(10 mg/kg负荷+2 mg/kg/h维持+1 mg/kg预充)轻度降低异体红细胞输注比例,并满足主要安全复合终点的非劣效标准。
  • 癫痫发生率在高剂量组1.0%与低剂量组0.4%间无统计学显著差异(P=0.05),原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Tranexamic acid is recommended for reducing blood loss and transfusion in cardiac surgery. However, it remains unknown whether a high dose of tranexamic acid provides better blood-sparing effect than a low dose without increasing the risk of thrombotic complications or seizures in cardiac surgery.

OBJECTIVE: To compare the efficacy and adverse events of high-dose vs low-dose tranexamic acid in patients undergoing cardiac surgery with cardiopulmonary bypass.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized clinical trial among adult patients undergoing cardiac surgery with cardiopulmonary bypass. The study enrolled 3079 patients at 4 hospitals in China from December 26, 2018, to April 21, 2021; final follow-up was on May 21, 2021.

INTERVENTIONS: Participants received either a high-dose tranexamic acid regimen comprising a 30-mg/kg bolus, a 16-mg/kg/h maintenance dose, and a 2-mg/kg prime (n = 1525) or a low-dose regimen comprising a 10-mg/kg bolus, a 2-mg/kg/h maintenance dose, and a 1-mg/kg prime (n = 1506).

MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the rate of allogeneic red blood cell transfusion after start of operation (superiority hypothesis), and the primary safety end point was a composite of the 30-day postoperative rate of mortality, seizure, kidney dysfunction (stage 2 or 3 Kidney Disease: Improving Global Outcomes [KDIGO] criteria), and thrombotic events (myocardial infarction, ischemic stroke, deep vein thrombosis, and pulmonary embolism) (noninferiority hypothesis with a margin of 5%). There were 15 secondary end points, including the individual components of the primary safety end point.

RESULTS: Among 3079 patients who were randomized to treatment groups (mean age, 52.8 years; 38.1% women), 3031 (98.4%) completed the trial. Allogeneic red blood cell transfusion occurred in 333 of 1525 patients (21.8%) in the high-dose group and 391 of 1506 patients (26.0%) in the low-dose group (risk difference [RD], -4.1% [1-sided 97.55% CI, -∞ to -1.1%]; relative risk, 0.84 [1-sided 97.55% CI, -∞ to 0.96; P = .004]). The composite of postoperative seizure, thrombotic events, kidney dysfunction, and death occurred in 265 patients in the high-dose group (17.6%) and 249 patients in the low-dose group (16.8%) (RD, 0.8%; 1-sided 97.55% CI, -∞ to 3.9%; P = .003 for noninferiority). Fourteen of the 15 prespecified secondary end points were not significantly different between groups, including seizure, which occurred in 15 patients (1.0%) in the high-dose group and 6 patients (0.4%) in the low-dose group (RD, 0.6%; 95% CI, -0.0% to 1.2%; P = .05).

CONCLUSIONS AND RELEVANCE: Among patients who underwent cardiac surgery with cardiopulmonary bypass, high-dose compared with low-dose tranexamic acid infusion resulted in a modest statistically significant reduction in the proportion of patients who received allogeneic red blood cell transfusion and met criteria for noninferiority with respect to a composite primary safety end point consisting of 30-day mortality, seizure, kidney dysfunction, and thrombotic events.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03782350.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Shi J, Zhou C, Pan W, et al. Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. JAMA. 2022. PMID: 35881121. doi:10.1001/jama.2022.10725

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。